Literature DB >> 26359308

Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement.

Petros Perros1, Colin M Dayan2, A Jane Dickinson3, Daniel G Ezra4, Janis L Hickey5, Christoph Hintschisch6, George Kahaly7, John H Lazarus2, Marian Ludgate2, Beate Bartès8, Caroline J MacEwen9, Anna L Mitchell1, Dan Morris10, Nicole O'Connor11, Simon H Pearce12, Geoffrey E Rose13, Mario Salvi14, Wilmar M Wiersinga15, Alyson Williamson11.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26359308      PMCID： PMC4652189          DOI： 10.1089/thy.2015.0222

Source DB:  PubMed          Journal:  Thyroid        ISSN： 1050-7256            Impact factor:   6.568


× No keyword cloud information.
  17 in total

1.  Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Alison J Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten P Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga
Journal:  Thyroid       Date:  2008-03       Impact factor: 6.568

Review 2.  Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yao Wang; Terry J Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

Review 3.  Mapping the impact of patient and public involvement on health and social care research: a systematic review.

Authors:  Jo Brett; Sophie Staniszewska; Carole Mockford; Sandra Herron-Marx; John Hughes; Colin Tysall; Rashida Suleman
Journal:  Health Expect       Date:  2012-07-19       Impact factor: 3.377

4.  Randomized controlled trial of rituximab in patients with Graves' orbitopathy.

Authors:  Marius N Stan; James A Garrity; Barbara G Carranza Leon; Thapa Prabin; Elizabeth A Bradley; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2014-10-24       Impact factor: 5.958

5.  Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation.

Authors:  Sajad Moshkelgosha; Po-Wah So; Neil Deasy; Salvador Diaz-Cano; J Paul Banga
Journal:  Endocrinology       Date:  2013-07-30       Impact factor: 4.736

6.  PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.

Authors:  Petros Perros; Miloš Žarković; Claudio Azzolini; Göksun Ayvaz; Lelio Baldeschi; Luigi Bartalena; Antonella Boschi; Claire Bournaud; Thomas Heiberg Brix; Danila Covelli; Slavica Ćirić; Chantal Daumerie; Anja Eckstein; Nicole Fichter; Dagmar Führer; Laszlo Hegedüs; George J Kahaly; Onur Konuk; Jürg Lareida; John Lazarus; Marenza Leo; Lemonia Mathiopoulou; Francesca Menconi; Daniel Morris; Onyebuchi Okosieme; Jaques Orgiazzi; Susanne Pitz; Mario Salvi; Cristina Vardanian-Vartin; Wilmar Wiersinga; Martine Bernard; Lucy Clarke; Nicola Currò; Colin Dayan; Jane Dickinson; Miroslav Knežević; Carol Lane; Claudio Marcocci; Michele Marinò; Lars Möller; Marco Nardi; Christopher Neoh; Simon Pearce; George von Arx; Fosun Baloş Törüner
Journal:  Br J Ophthalmol       Date:  2015-05-07       Impact factor: 4.638

7.  Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.

Authors:  L Bartalena; G E Krassas; W Wiersinga; C Marcocci; M Salvi; C Daumerie; C Bournaud; M Stahl; L Sassi; G Veronesi; C Azzolini; K G Boboridis; M P Mourits; M R Soeters; L Baldeschi; M Nardi; N Currò; A Boschi; M Bernard; G von Arx
Journal:  J Clin Endocrinol Metab       Date:  2012-10-04       Impact factor: 5.958

8.  Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Authors:  Mario Salvi; Guia Vannucchi; Nicola Currò; Irene Campi; Danila Covelli; Davide Dazzi; Simona Simonetta; Claudio Guastella; Lorenzo Pignataro; Sabrina Avignone; Paolo Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2014-12-15       Impact factor: 5.958

9.  Description and evaluation of the first national patient and public involvement day for thyroid eye disease in the United Kingdom.

Authors:  Henry B Smith; Carol Porteous; Catey Bunce; Karen Bonstein; Janis Hickey; Colin M Dayan; Gill Adams; Geoff E Rose; Daniel G Ezra
Journal:  Thyroid       Date:  2014-07-21       Impact factor: 6.568

10.  Public health relevance of Graves' orbitopathy.

Authors:  Katharina A Ponto; Sonja Merkesdal; Gerhard Hommel; Susanne Pitz; Norbert Pfeiffer; George J Kahaly
Journal:  J Clin Endocrinol Metab       Date:  2012-11-26       Impact factor: 5.958
View more
  3 in total

1.  Guidance on That Damned Elusive Orbitopathy of Graves' Disease.

Authors:  Peter Laurberg
Journal:  Eur Thyroid J       Date:  2016-03-09

2.  What Matters to Whom: Patient and Public Involvement in Research.

Authors:  Karen J Gibbins; Jamie O Lo
Journal:  Clin Obstet Gynecol       Date:  2022-02-18       Impact factor: 1.966

3.  Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.

Authors:  P Perros; L Hegedüs; L Bartalena; C Marcocci; G J Kahaly; L Baldeschi; M Salvi; J H Lazarus; A Eckstein; S Pitz; K Boboridis; P Anagnostis; G Ayvaz; A Boschi; T H Brix; N Currò; O Konuk; M Marinò; A L Mitchell; B Stankovic; F B Törüner; G von Arx; M Zarković; W M Wiersinga
Journal:  Orphanet J Rare Dis       Date:  2017-04-20       Impact factor: 4.123
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.